235 related articles for article (PubMed ID: 35194731)
41. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
Park HS; Sohn J; Kim SI; Park S; Park HS; Gho SG; Chung HC; Paik S; Kim GM
Breast Cancer Res Treat; 2017 Jun; 163(2):255-262. PubMed ID: 28243895
[TBL] [Abstract][Full Text] [Related]
42. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study.
Cazzaniga ME; Vallini I; Montagna E; Amoroso D; Berardi R; Butera A; Cagossi K; Cavanna L; Ciccarese M; Cinieri S; Cretella E; De Conciliis E; Febbraro A; Ferraù F; Ferzi A; Baldelli A; Fontana A; Gambaro AR; Garrone O; Gebbia V; Generali D; Gianni L; Giovanardi F; Grassadonia A; Leonardi V; Marchetti P; Sarti S; Musolino A; Nicolini M; Putzu C; Riccardi F; Santini D; Saracchini S; Sarobba MG; Schintu MG; Scognamiglio G; Spadaro P; Taverniti C; Toniolo D; Tralongo P; Turletti A; Valenza R; Valerio MR; Vici P; Di Mauro P; Cogliati V; Capici S; Clivio L; Torri V;
Breast Cancer Res Treat; 2021 Dec; 190(3):415-424. PubMed ID: 34546500
[TBL] [Abstract][Full Text] [Related]
43. Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre.
Twelves C; Cheeseman S; Sopwith W; Thompson M; Riaz M; Ahat-Donker N; Myland M; Lee A; Przybysz R; Turner S; Hall G; Perren T
BMC Cancer; 2020 Jan; 20(1):53. PubMed ID: 31964373
[TBL] [Abstract][Full Text] [Related]
44. Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).
Macalalad AR; Hao Y; Lin PL; Signorovitch JE; Wu EQ; Ohashi E; Zhou Z; Kelley C
Curr Med Res Opin; 2015 Feb; 31(2):263-73. PubMed ID: 25350226
[TBL] [Abstract][Full Text] [Related]
45. Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation.
Boudin L; Chabannon C; Sfumato P; Sabatier R; Bertucci F; Tarpin C; Provansal M; Houvenaeghel G; Lambaudie E; Tallet A; Resbeut M; Charafe-Jauffret E; Calmels B; Lemarie C; Boher JM; Extra JM; Viens P; Gonçalves A
Eur J Cancer; 2016 Apr; 57():118-26. PubMed ID: 26918737
[TBL] [Abstract][Full Text] [Related]
46. Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US.
Li N; Hao Y; Kageleiry A; Peeples M; Fang A; Koo V; Wu EQ; Guérin A
Curr Med Res Opin; 2016; 32(2):385-94. PubMed ID: 26651842
[TBL] [Abstract][Full Text] [Related]
47. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021.
Jaber Chehayeb R; Hood A; Wang X; Miksad R; Schellhorn Mougalian S; Lustberg MB; Wang SY; Greenup RA; Pusztai L; Kunst N
JAMA Netw Open; 2022 Nov; 5(11):e2244204. PubMed ID: 36445704
[TBL] [Abstract][Full Text] [Related]
48. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
49. Survival Outcomes Among Patients with Metastatic Breast Cancer: Review of 47,000 Patients.
Taskindoust M; Thomas SM; Sammons SL; Fayanju OM; DiLalla G; Hwang ES; Plichta JK
Ann Surg Oncol; 2021 Nov; 28(12):7441-7449. PubMed ID: 34050430
[TBL] [Abstract][Full Text] [Related]
50. Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort.
Epaillard N; Lusque A; Jacot W; Mailliez A; Bachelot T; Arnedos M; Le Du F; Brain E; Ferrero JM; Massard V; Desmoulins I; Mouret-Reynier MA; Levy C; Gonçalves A; Leheurteur M; Petit T; Filleron T; Bosquet L; Pistilli B; Frenel JS
ESMO Open; 2024 May; 9(5):103447. PubMed ID: 38703431
[TBL] [Abstract][Full Text] [Related]
51. Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
Kotsakis A; Ardavanis A; Koumakis G; Samantas E; Psyrri A; Papadimitriou C
BMC Cancer; 2019 Jan; 19(1):88. PubMed ID: 30658600
[TBL] [Abstract][Full Text] [Related]
52. Risk and prognostic factors of breast cancer with liver metastases.
Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
[TBL] [Abstract][Full Text] [Related]
53. Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China.
Li J; Wang S; Wang Y; Wang X; Wang H; Feng J; Zhang Q; Sun T; Ouyang Q; Yin Y; Liu Y; Geng C; Yan M; Jiang Z
Oncologist; 2017 Nov; 22(11):1333-1338. PubMed ID: 28798274
[TBL] [Abstract][Full Text] [Related]
54. Overall Survival of Men and Women With Breast Cancer According to Tumor Subtype: A Population-based Study.
Leone J; Zwenger AO; Leone BA; Vallejo CT; Leone JP
Am J Clin Oncol; 2019 Feb; 42(2):215-220. PubMed ID: 30499840
[TBL] [Abstract][Full Text] [Related]
55. Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer.
West MT; Goodyear SM; Hobbs EA; Kaempf A; Kartika T; Ribkoff J; Chun B; Mitri ZI
Oncologist; 2023 Aug; 28(8):682-690. PubMed ID: 36946994
[TBL] [Abstract][Full Text] [Related]
56. Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer.
Osborne C; Challagalla JD; Eisenbeis CF; Holmes FA; Neubauer MA; Koutrelakos NW; Taboada CA; Vukelja SJ; Wilks ST; Allison MA; Reddy P; Sedlacek S; Wang Y; Asmar L; O'Shaughnessy J
Clin Breast Cancer; 2018 Feb; 18(1):e89-e95. PubMed ID: 28779904
[TBL] [Abstract][Full Text] [Related]
57. Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database.
Burton T; Byfield SD; Smith GL; Zanotti G; Bell TJ; Perkins JJ; Horblyuk R; Teitelbaum A
Curr Med Res Opin; 2016 Aug; 32(8):1417-23. PubMed ID: 27074160
[TBL] [Abstract][Full Text] [Related]
58. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy.
Seah DS; Luis IV; Macrae E; Sohl J; Litsas G; Winer EP; Lin NU; Burstein HJ
J Natl Compr Canc Netw; 2014 Jan; 12(1):71-80. PubMed ID: 24453294
[TBL] [Abstract][Full Text] [Related]
59. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
Wong Y; Raghavendra AS; Hatzis C; Irizarry JP; Vega T; Horowitz N; Barcenas CH; Chavez-MacGregor M; Valero V; Tripathy D; Pusztai L; Murthy RK
Oncologist; 2019 Mar; 24(3):313-318. PubMed ID: 30139836
[TBL] [Abstract][Full Text] [Related]
60. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
